A股異動丨高瀾股份大漲近7% 收購東莞硅翔方案獲股東大會通過
格隆匯10月21日丨高瀾股份(300499.SZ)大漲近7%,報13.63元,成交6939萬元,總市值25億元。

10月17日,高瀾股份股東大會審議通過了公司購買東莞市硅翔絕緣材料有限公司51%股權、發行可轉債和更換公司董事、監事在內的多項議案。高瀾股份董事長李琦認為,此次多項議案的順利通過,體現了公司戰略的高度統一及執行的有效落地。通過本次收購,公司可以進一步完善“新產品、新領域、新區域”三新業務發展戰略在新領域的應用佈局,進入具有廣闊發展前景的新能源汽車產業鏈,增加新的利潤增長點,有利於提升公司整體盈利水平,成為實現公司業務橫向一體化發展的有利契機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.